← All trials
NCT06580444
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 24, 2024
- Primary completion
- Feb 26, 2027
- Completion date
- Mar 19, 2027
- First posted
- Aug 30, 2024
- Last posted
- Aug 30, 2024
- Enrollment
- 40
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Pharmacotherapies for Alcohol and Substance Abuse ConsortiumLead sponsor
- RTI InternationalCollaborator
- Yale UniversityCollaborator
- Sage TherapeuticsCollaborator
- Department of DefenseCollaborator
- Department of DefenseCollaborator
- Department of Veteran AffairsCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.